KDR and nasopharyngeal carcinoma: Apatinib selectively inhibits vascular endothelial growth factor receptor-2 (VEGFR-2)22 and showed activity against RM-NPC in several reports.23-25 In this phase II study, we assessed the antitumor activity and safety of camrelizumab plus apatinib in patients with NPC who were refractory to one line of systemic therapy.